Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 10/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | FNTA | P49354 | 3/20 | 0.32 |
| ▸ | FNTB | P49356 | 3/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180224 | 0.88 | CYP17A1 (0.47) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL5569827 | 0.83 | CYP17A1 (0.45) | CYP17A1CYP19A1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL1180028 | 0.81 | CYP19A1 (0.49) | CYP17A1CYP19A1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL5573331 | 0.81 | CYP17A1 (0.41) | CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL5569838 | 0.81 | CYP17A1 (0.41) | CYP17A1CYP19A1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL1768475 | 0.77 | CYP11B1 (0.34) | CYP17A1CYP19A1CYP11B1CYP11B2FNTA | |
| SCHEMBL1180719 | 0.77 | CYP17A1 (0.52) | CYP17A1 | |
| SCHEMBL1180760 | 0.75 | CYP17A1 (0.42) | CYP17A1CYP19A1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL5048062 | 0.73 | CYP19A1 (0.48) | CYP17A1CYP19A1KCNH2CYP11B1CYP11B2 | |
| SCHEMBL5571001 | 0.73 | CYP19A1 (0.48) | CYP17A1CYP19A1KCNH2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| US-8263615-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2012-09-11 | — | — | US | disclosed |
| CN-101326184-B | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG | 2011-11-23 | — | — | CN | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| US-8008334-B2 | Bis-heterocyclic imidazolyl compounds | NOVARTIS AG (CH) | 2011-08-30 | — | — | US | disclosed |
| CN-102115473-A | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG | 2011-07-06 | — | — | CN | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | HEROLD PETER | 2011-02-03 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | NOVARTIS AG (CH) | 2009-08-06 | — | — | US | disclosed |
| CN-101326184-A | Bis-heterocyclic imidazolyl compounds | SPEEDEL EXPERIMENTA AG (CH) | 2008-12-17 | — | — | CN | disclosed |
| EP-1957489-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | Speedel Experimenta AG (CH) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065942-A2 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028512-A1 | BIS-HETEROCYCLIC IMIDAZOLYL COMPOUNDS | CYP11B1, CYP11B2, REN | CYP17A1 10/4885CYP19A1 43/4885KCNH2 1222/4885 |
| US-20090197909-A1 | Bis-Heterocyclic Imidazolyl Compounds | REN, CYP11B1, CYP11B2 | CYP17A1 13/4885CYP19A1 92/4885KCNH2 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.